Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PURPOSE: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were exclude...

全面介紹

Na minha lista:
書目詳細資料
發表在:PLoS One
Main Authors: Zimmer, Lisa, Vaubel, Julia, Mohr, Peter, Hauschild, Axel, Utikal, Jochen, Simon, Jan, Garbe, Claus, Herbst, Rudolf, Enk, Alexander, Kämpgen, Eckhart, Livingstone, Elisabeth, Bluhm, Leonie, Rompel, Rainer, Griewank, Klaus G., Fluck, Michael, Schilling, Bastian, Schadendorf, Dirk
格式: Artigo
語言:Inglês
出版: Public Library of Science 2015
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356548/
https://ncbi.nlm.nih.gov/pubmed/25761109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0118564
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍